China's Kintor hits record low as COVID treatment trial misses statistical criteria

Kintor Pharmaceutical

28/12/2021 03:44

** Shares of China's Kintor Pharmaceutical Ltd  9939.HK 
plunge as much as 84.7% to record low of HK$6.91, set for
biggest daily percentage drop since debut in May 2020
    ** Stock is the biggest percentage decliner on the Hong Kong
bourse and on Hang Seng Composite Index  .HSCI ; fifth-most
actively traded by turnover in late morning
    ** Jiangsu-based Kintor said data from a Phase III clinical
trial for its potential COVID-19 treatment, proxalutamide, in
non-hospitalised patients did not meet statistical criteria in
the interim analysis due to the low number of hospitalisations
 urn:newsml:reuters.com:*:nL1N2TC0H3
    ** Kintor said it will seek consent from authorities
including U.S. Food and Drug Administration to amend clinical
protocol and continue to enrol patients of higher risk, such as
those who have not received a COVID-19 vaccination
    ** Hong Kong's healthcare index  .HSCIH  falls 1.3%
    ** Hang Seng Composite Index  .HSCI  slips 0.3% and the
benchmark Hang Seng Index  .HSI  eases 0.1%
    ** Stock had soared 332.1% this year, as of last close 

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))